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1.1. SCHIZOPRENIA 
 
Schizophrenia is a severe mental disorder characterized by a breakdown of thought 
processes and by a deficit of typical emotional responses. Common symptoms are 
delusions including paranoia and auditory hallucinations, disorganized thinking 
reflected in speech, and a lack of emotional intelligence. It is accompanied by 
significant social or vocational dysfunction. The onset of symptoms typically occurs in 
adolescents and early adulthood, and around 4 years earlier in males than females. 
The median incidence (25% and 75% quantiles) is 15.2 (10.2-22.0) per 100,000 
persons, while the median lifetime prevalence (25%, 75% quantiles) is 4.0 (3.0-6.6) per 
1,000 persons (McGrath et al. 2008). Aetiology and pathophysiology remain unknown; 
however, it is widely accepted that a combination of genetic, environment and 
psychosocial factors lead to the manifestation of the illness (van Os and Kapur 2009). 
Heritability in schizophrenia is around 80%, so genetic risk factors are important in the 
development of the disorder. The greatest risk factor for developing schizophrenia is 
having a first degree with the disease, with an odds ratio of nearly ten (Sullivan et al, 
2005). A large amount of genome-wide linkage studies and association studies have 
been conducted to elucidate the genetic variations involved in schizophrenia but still 
have not been identified susceptibility genes 
 
 
Figure 1. Schematic representation of the proposed etiopathogenic model for  
schizophrenia based on the interaction of genetic and environmental factors.  
Source: Picker J (2005) 
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1.2. MITOCHONDRIA 
 
Mitochondria are subcellular organelles enriched in energetic tissues, such as muscle 
and brain, and located in the cytoplasm. Although there are over 1500 human 
mitochondrial genes (Wallace, 2005), only a small fraction of these are directly 
encoded by the mitochondrial DNA (mtDNA). The mitochondrial genome has several 
different characteristics from the nuclear genome. Human mtDNA, which is inherited in a 
matrilineal pattern (Giles et al., 1980), is a double stranded circular molecule of 
approximately 16.569 nucleotides (Wallace, 2005) containing 37 genes that encode 
two ribosomal RNAs, 22 transfer RNAs, and 13 polypeptides. Interestingly, it codifies 
for 13 of the 84 subunits of the mitochondrial respiratory chain that are crucial for its 
function. Also, it has a non-codifying region, the D-loop, involved in mtDNA replication 
and transcription regulation. One of the most important functions of mitochondria is to 
generate energy and for this reason it is important in tissues with high-energy 
requirements such as brain and muscle. The number of mitochondria in a somatic cell 
varies between 200 and 2000. Spermatozoa contain 16 mitochondria, whereas oocytes 
can hold up to 100,000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Mitochondrial DNA 
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Figure 3. The human mitochondrial genome. 
mtDNA is a 16,569 double-strand DNA molecule. The different regions of the 
mtDNA are shown in distinct colours. The 13 genes that encode for the 
essential components of the respiratory chain are shown in yellow (subunits of 
complex I), red (subunit of complex III), blue (subunits of complex IV) and green 
(subunits of complex V) . 
 
 
Mitochondrial genetics involves specific characteristics that differ from nuclear genetics: 
 
- Uniparental inheritance. MtDNA is only inherited from the mother (non-
mendelian inheritance) 
- Human mtDNA genetic code differs from the universal code 
 
Table 1. Differences between the mtDNA and the nDNA 
codon mtDNA nDNA 
AUA Initiation code (Met) Arginine 
AUG Initiation code (Met)  
AGA, AGG Termination codes Arginine 
UGA Tryptophan Termination 
Isoleucine during elongation  
AUU 
Methionine during initiation  
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- High substitution rate. mtDNA is particularly susceptible to a higher rate of 
somatic deletions because mtDNA is not protected by histones and lacks of a 
complete set of DNA repair machinery as it is associated with nuclear DNA. 
Mutation rates are higher in mtDNA compared to nuclear DNA, and mutation 
rates are particularly high in non-coding regions of the mtDNA in human brain 
such as the hypervariable region of the mtDNA genome. The susceptibility of 
mtDNA to somatic mutations can lead to a gradual accumulation of germinal 
mutations along the transmission of the mtDNA through generations, giving rise 
to the differences among populations and among individuals. Also, it has been 
hypothesized that mtDNA may be also involved in complex traits including 
neurodegenerative disorders, ageing and cancer (Schon et al. 2012). 
 
- Poliploidy. Each human cell contains different number of mitochondria, 
depending on its energy requirement, and also a lot of copies of mtDNA. All these 
copies of mtDNA are identical in healthy subjects but in some conditions, patients 
can present mutated molecules and wild type molecules. Homoplasmy refers to 
the condition in which all mtDNA molecules are identical and heteroplasmy refers 
to the existence of subpopulations of mtDNA genomes within an individual. 
 
- Highly polymorphic. Specific patterns of polymorphisms are the basis of the 
mtDNA haplogroups. A mtDNA haplogroup is a certain group of polymorphisms 
that reflect the maternal ancestry of a particular individual that is characteristic 
and it is specific for different ethnic groups (although there are differences 
between individuals that are included in the same ethnic group). Each haplogroup 
contains individual haplotypes that are specific mitochondrial genotypes defined 
by a characteristic collection of mtDNA polymorphisms. When a sample is 
analysed, the first thing to do is to determine the haplogroup that it belongs to 
looking at the mitochondrial genotype (the mtDNA variants that define the 
haplotype) and the rest of the variants that are not defining the haplotype of the 
samples are those candidates to further studies. MtDNA variants have been 
reported to occur in almost every nucleotide position of the 16.569 bp 
mitochondrial genome. Although most reported common recurrent pathogenic 
mutations are heteroplasmic, the rare variants associated with common 
complex diseases such as diabetes or hypertension are often homoplasmic. 
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1.3. MITOCHONDRIAL DISORDERS  
 
When we talk about mitochondrial disorders, we refer to disorders with mitochondrial 
dysfunction that can result from the nuclear DNA or mtDNA mutations. Mitochondrial 
disorders, resulting from point mutations or rearrangements of the mtDNA have been 
associated with a variety of clinical presentations. Point mutations are typically 
maternally inherited. 
Mutations in the mtDNA cause mitochondrial disorders that can present either in 
infancy or adulthood. More than 150 genetic mitochondrial syndromes have been 
described affecting 1 in 5,000 live births (Skladal et al. 2003). Signature traits are lactic 
acidosis, skeletal myopathy, deafness, blindness, subacute neurodegeneration, 
intestinal dismotility and peripheral neuropathy. Though most organ systems can be 
affected it is also possible a highly tissue-specific dysfunction (Vafai and Mootha 2012) 
 
 
1.4. THE mtDNA AND SCHIZOPHRENIA 
 
The hypothesis of mtDNA involvement in the schizophrenia’s genetic susceptibility is 
supported from several perspectives. Briefly, mitochondrial dysfunction, maternal 
inheritance and also comorbidity of schizophrenia and mitochondrial disorders related 
to mtDNA mutations have been reported (Verge et al. 2011; Anglin et al. 2012). 
Moreover, the mitochondrial dysfunction in schizophrenia has been hypothesised as an 
explanation for the heterogeneity of clinical and pathological manifestations and the 
mtDNA has been indicated as an underlying etiologic genetic factor. However, the 
mitochondrial dysfunction that has been proposed to be involved in schizophrenia may 
be related to an abnormal function of nuclear, mitochondrial or both types of genomes. 
 
One possible indication of a mitochondrial disorder is a matrilineal inheritance 
(Wallace, 1994). For neuropsychiatric disorders such as schizophrenia, higher rates of 
disease are observed in offspring of maternal probands compared to offspring of 
paternal probands (Verge et al, 2011). 
 
Mitochondria provide most of the energy for brain cells by the process of oxidative 
phosphorylation. Mitochondrial abnormalities and deficiencies in oxidative 
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phosphorylation have been reported in individuals with schizophrenia, bipolar disorder 
and major depressive disorder in transcriptomics, proteomics and metabolomics 
studies (Zaragoza MV et al, 2010. Cacabelos R, 2011). 
 
Human mtDNA variants have been studied related to the human health and the illness. 
It is well known that specific mutations and some variants are involved in human 
disorders. It has also been described that some of these variants and mutations are 
related with neuropsychiatric disorders. And finally, severe mental conditions such as 
psychoses or depression have been described in adult patients of mitochondrial illness 
caused by a mtDNA mutation. The brain disorders that appear from mtDNA changes 
are divided in two groups: sporadic diseases mainly due to rearrangements in the 
mtDNA and maternally inherited diseases due to point mutations. One of the previous 
steps in the study of mtDNA in mental disorders was to study the mtDNA association in a 
small number of subjects, focused on rare mutations or haplogroup-defining SNPs and 
have no found compelling evidence for association (a case-control study). (Hudson G, 
2013) There are few studies of mtDNA in schizophrenic patients and most of them do not 
support the association of particular mtDNA variant with an increased risk of 
schizophrenia (reviewed in Mosquera-Miguel et al, 2013). 
 
Sequence variants in mtDNA can be present in all the mtDNA molecules of a 
participant (homoplasmy) or may occur only in a subpopulation of mtDNA copies 
(heteroplasmy). The percentage of mutation heteroplasmy can vary among different 
tissues, contributing to the high variability in clinical features and disease severity. The 
proportion of normal and mutant molecules in a specific tissue (heteroplasmy level) 
largely determines the clinical expression of a pathogenic mtDNA. Determining the 
heteroplasmy level is important because it is related to the degree of mitochondrial 
dysfunction and disease severity. 
 
There is no single variant that should be considered an a priori candidate to be 
involved in schizophrenia. Thus, the study of the entire mtDNA is more appropriate. 
The two methods most widely used to identify mtDNA variants are direct Sanger 
sequencing and the Affymetrix GeneChip Human Mitochondrial Resequencing Array; 
however, these two methods are neither sensitive nor specific enough to detect 
heteroplasmy.  
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1.5. NEXT GENERATION SEQUENCING BY ION TORRENT (PGM) 
 
In this project, the mitochondrial DNA resequencing was done by Next Generation 
Sequencing (NGS) using the ION TORRENT sequencer (PGM, Life Technologies). 
mtDNA from patients was first amplified in two overlapping fragments and purified prior 
to start with the sequencing protocol. DNA sequencing is the process of determining 
the precise order of nucleotides within a DNA molecule. NGS allows large numbers of 
DNA molecules to be sequenced per run, and therefore, at low reagent costs. 
 
In the benchtop group of sequencers, The Ion Torrent Personal Genome Machine 
(PGM) has been recently introduced. This sequencer is the first to use semiconductors 
and a non-optical based sequencing technology [Rothberg et al., 2011]. It is a NGS 
equipment that allows to sequence large amounts of nucleic acids chains. The 
detection system is based on changes of ionic potential. This PGM has an informatics 
server with software (Torrent Suite) where the data is filtered and also mapped with the 
reference genome that is required to be indicated and there is also a primary quality 
control. These semi-raw data have to be analysed using different tools as it is 
explained in the methodology section. 
 
 
 
Figure 4. ION TORRENT PGM (Life Technologies) and a brief view of its chemistry. 
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The aim of this final master project is to identify mtDNA variants or mutations in 
schizophrenia patients with an apparent matrilineal heredity of this disorder. This 
present study is involved in a project where the main goal is identify mtDNA variants or 
mutations in schizophrenia patients with an apparent matrilineal heredity of this 
disorder and to investigate whether the mtDNA mutations identified could contribute to 
the mitochondrial dysfunction described in schizophrenia.  
 
This final master project has performed to accomplish three main objectives: 
 
- To establish and standardize the bioinformatics analysis using free software of 
the NGS data obtained with the equipment Ion Torrent PGM.  
 
- To identify new variants and apply bioinformatics prediction tools to assess the 
possible implications by the prediction of pathogenicity of non-synonymous 
variants and to determine if they can be related with schizophrenia.  
 
- To identify whether some of the identified variants were more frequent in cases 
than in control subjects, and therefore, susceptible to account for schizophrenia 
risk. 
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3.  SUBJECTS AND METHODS 
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3.1. SUBJECTS 
 
This study was carried out with the approval of the Sant Joan University Hospital Ethics 
Committee from Reus and written informed consent was obtained from schizophrenia 
patients and control individuals after full explanation of the procedures. Blood samples 
were obtained from peripheral blood and the DNA isolated from leucocytes. 
Patients and controls were from the same geographical region and had similar ethnic 
background. The control group was comprised by 38 individuals and they had no life 
history of psychiatric symptoms or first-degree relatives with psychiatric disorders. The 
group of patients was comprised by 55 schizophrenia patients with apparent matrilineal 
inheritance of the disease to identify variants and/or mutations. 
 
 
3.2. mtDNA SEQUENCING BY NGS 
 
This resequencing step was done by NGS with the Ion Torrent PGM (Life 
Technologies). This ionic sequencing technique allows sequencing high amount of 
nucleic acids in a short time. The detection system is based in ionic potential changes 
that happen when a nucleotide binds to the elongation sequence. 
 
The mtDNA of each participant was amplified in two fragments of 8338 and 8647 bp 
using previously described primers (Gunnarsdottir et al., 2011). Long-range PCR was 
performed using 10 ng of DNA with Expand Long Range dNTPack (Roche, Barcelona, 
Spain), and the PCR products were purified using the QIAquick PCR Purification kit 
(Qiagen) following the manufacturer's instructions. Lastly, the two PCR fragments from 
each individual were mixed in equimolar ratios for the sequencing protocol using the 
Ion Torrent Personal Genome Machine (PGM) according to the manufacturer’s user 
guide. In short, 200-bp libraries were generated using the AB Library Builder System 
and the Ion Xpress Plus Fragment Library kit (Life Technologies). The samples were 
barcoded using the Ion Xpress Barcode Adapter 1-16 (Life Technologies), and the 
library concentration and amplicon size were assessed with the Agilent Bioanalyzer 
High Sensitivity DNA kit (Agilent, Madrid, Spain) using the Agilent Bioanalyzer. 
Equimolar pools of barcoded libraries were mixed to run the samples on the Ion 314 
chips. The template of the library pool was prepared using the Ion OneTouch 200 
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Template kit v2 DL (Life Technologies), and sequencing was performed with the Ion 
PGM 200 Sequencing Kit (Life Technologies). 
The PGM has an informatics server (Torrent server) were the sequencing data are 
dumped and by the Torrent Suite Software, a first filtering process and a quality step of 
the data are done. This data have been analysed by different bioinformatics tools 
established in a pipeline. 
 
In the new NGS platforms, as Ion Torrent PGM, low percentages of heteroplasmy can 
be detected; however false positives variants are also identified, demonstrating low 
specificity (Tang S. et al, 2010). As we previously mentioned, determining the 
heteroplasmy level is important because it is related to the degree of mitochondrial 
dysfunction and disease severity. Therefore, it is important to indicate whether a 
change is homoplasmic or heteroplasmic and also it is of interest to know the 
technology capacity to detect it. Also, it is necessary to distinguish a true low level of 
heteroplasmy from an apparent heteroplasmy due to a technical artefact from poor 
DNA sequence quality. For this reason is needed to check the results obtained by Next 
Generation Sequencing by Sanger Sequencing. The same heteroplasmic change 
should be identified in both sequencing directions by Sanger sequencing and there 
should be no sequence background in the adjacent regions. If there are multiple 
heteroplasmic changes detected in one individual, further investigations are needed to 
verify the heteroplasmic finding.  
 
 
3.3. SEQUENCING DATA ANALYSIS AND VARIANT IDENTIFICATION 
 
The resulting sequences were aligned and compared to the revised Cambridge 
Reference Sequence, rCRS, NC_012920.1 (Andrews et al, 1999). 
To perform a variant identification we established a basic pipeline using different 
bioinformatics tools.  
 
a) Checking the quality of the reads. View the fastq files.  
b) Sort the bam file. 
c) Remove possible PCR duplicates.  
FINAL MASTER PROJECT_MARTA RODRIGUEZ BALADA 
 
 
17 
 
d) Index the bam file. It generates a bai file that is needed for some display 
and snp calling programs.  
e) Get some statistics using SAMtools. . (Li et al., 2009) 
f) Perform variant calling with SAMtools.  
g) Variant filtering. We need to filter variants from the raw vcf file. To do 
that we use samtools.  
h) Visualize the SNPS on IGV (loading the bam file, sorted and without 
PCR duplicates). 
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Figure 5. Pipeline to analyze the Ion Torrent data 
 
 
 
 
 
 
 
 
 
 
 
#Sort the bam file 
 
samtools sort P066_IonXpress_005_R_2013_07_30_05_00_15_user_PGM-
23-Xip_6_Helena_Auto_user_PGM-23-Xip_6_Helena_24.bam 
p066_sorted.bam 
 
# Remove possible pcr duplicates 
samtools rmdup -s p066_sorted.bam.bam p066_sorted.noDup.bam.bam 
 
# Index the bam file 
samtools index p066_sorted.noDup.bam.bam 
 
# GEt some stats using samtools 
samtools flagstat p066_sorted.noDup.bam.bam  
 
############################ 
### Perform variant calling with samtools 
 
samtools mpileup -uf sequence.fasta p066_sorted.noDup.bam.bam | 
bcftools view -vcg - > 
p066_sorted.noDup.bam.bam.samtools.var.raw.vcf  
 
.../samtools-0.1.19/bcftools/vcfutils.pl varFilter -Q 10 -d 15 -a 
5 p066_sorted.noDup.bam.bam.samtools.var.raw.vcf > 
p066_sorted.noDup.bam.bam.samtools.var.filtered.vcf 
 
 
#less -s p066_sorted.noDup.bam.bam.samtools.var.filtered.vcf 
 
# to obtain a txt file with the variant list 
tail -n +2 p066_sorted.noDup.bam.bam.samtools.var.filtered.vcf | 
cut -f2-10 > p066_sorted.noDup.bam.bam.samtools.var.filtered.txt 
 
#ls -la *vcf 
 
 
########################### 
# View aligned files using IGV 
cd IGV_2.3.3/ 
./igv.sh 
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3.4. BIOINFORMATIC TOOLS 
 
To perform the bioinformatics analysis of the data obtained after sequencing all the 
samples, we need several bioinformatics tools to check the quality of the data, to filter 
and process it and also it is interesting to use a viewer to explore the data processed. 
 
3.4.1. FASTQC 
FastQC software allows making a post run quality check and making a read quality 
trimming. It aims to provide a tool to do some quality control checks on raw sequence 
data coming from the Next Generation Sequencer. It consists on a modular set of 
analyses which we can use to have a quick report to know if our data has any problems 
during the sequencing process of which we should be aware before doing any further 
analysis.  
The main functions of FastQC are  
• Import of data from BAM, SAM or FastQ files 
• Providing a quick overview of the sequencing process 
• Summary graphs and tables to quickly assess our data 
To use this tool, FASTQ files are needed. FASTQ files extend FASTA files in that they 
provide both sequence and quality data. A FASTQ file thus typically consists of four 
lines of information. 
1. The sequence identifier: a line starting with @ containing the sequence 
identifier 
2. The actual sequence 
3. A line starting with + after which the sequence identifier is optional 
4. Quality data: a line with quality values which are encoded in ASCII space 
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Figure 5. Example of a FASTQ file 
 
 
There are several quality parameters that we have to consider to explore the quality of 
our sequences: 
 
3.4.1.1. Sequence Quality 
The quality score introduced in the FASTQ files. It gives an idea about base call 
quality. Quality of reads often degrades over the course of a sequence. Looking to the 
bar plots that show the quantiles, we can have an idea about the spread of the quality. 
 
3.4.1.2. Per Base Sequence Content 
Base content at each position is an important quality indicator. When we want to know 
the per base sequence content, we assume that the contribution should be identical at 
each position. What we expect is to see straight lines; however the first few bases 
might indeed show some variability in base content. This is likely, due to non-
completely random primers, but then we expect stability.  
 
3.4.1.3. Introduction of errors and quality scores/encoding 
As mentioned above the base caller assigns a quality score for each base. This score 
gives the estimated reliability for each individual. Ion Torrent has major issues with 
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homopolymers such as AAAAAA where the correct number of As can often not be 
determined exactly. 
 
3.4.1.4. Preprocessing Steps 
In order to avoid quality data problems, a common strategy is to remove low quality 
bases by sequence quality trimming. Typically one would remove lower quality bases 
from the 3' end using a sliding windows approach as per base quality gradually drops. 
In addition to removing lower base quality data, one would also remove adapters, PCR 
primers and other artefacts. It can be done by Alternative clipping strategies (Adaptor 
clipping).In practice one would combine the adapter clipping with quality trimming 
approaches. 
 
 
A typical quality control workflow consist of having a look to the quality plots from the 
raw data obtained by the sequencer (the raw data) and to evaluate them to know 
whether there have been problems during the library preparation process. Thereafter, 
make a trimming to remove errors. There are several tools that can be used, e.g. 
Trimmomatic, to remove bases presenting low quality values from the sequence ends 
and to remove the adapters from the reads. Finally, it is important to have a look to the 
post-trimming quality plots to judge the final quality of the sequences. 
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Figure 6. Report of an Ion Torrent chip generated by FASTQC 
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3.4.2. SAMTOOLS 
SAM files consist of two types of lines: headers and alignments.  
- Headers begin with @, and provide meta-data regarding the entire alignment 
file.  
- Alignments begin with any character except @, and describe a single alignment 
of a sequence read against the reference genome. 
Each read in a FASTQ file may align to multiple regions within a reference genome, 
and an individual read can therefore result in multiple alignments. In the SAM format, 
each of these alignments is reported on a separate line. Each alignment has 11 fields, 
followed by a variable number of optional fields. Each of the fields is described in the 
table 2. 
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Table 2. Mandatory fields and optional fields of a SAM file. 
FIELD NAME DESCRIPTION 
QNAME Unique identifier of the read; derived from the original FASTQ file 
FLAG 
A single integer value which encodes multiple elements of meta-
data regarding a read and its alignment. Elements include: 
whether the read is one part of a paired-end read, whether the 
read aligns to the genome, and whether the read aligns to the 
forward or reverse strand of the genome 
RNAME Reference genome identifier. 
POS 
Left-most position within the reference genome where the 
alignment occurs. 
MAPQ 
Quality of the genome mapping. The MAPQ field uses a Phred-
scaled probability value to indicate the probability that the 
mapping to the genome is incorrect. Higher values indicate 
increased confidence in the mapping 
CIGAR 
A compact string that (partially) summarizes the alignment of the 
raw sequence read to the reference genome. Three core 
abbreviations are used: M for alignment match; I for insertion; and 
D for Deletion 
RNEXT 
Reference genome identifier where the mate pair aligns. Only 
applicable when processing paired-end sequencing data. 
PNEXT 
Position with the reference genome, where the second mate pair 
aligns. As with RNEXT, this field is only applicable when 
processing paired-end sequencing data. A value of 0 indicates 
that information is not available. 
TLEN 
Template Length. Only applicable for paired-end sequencing data, 
TLEN is the size of the original DNA or RNA fragment, determined 
by examining both of the paired-mates, and counting bases from 
the left-most aligned base to the right-most aligned base. A value 
of 0 indicates that TLEN information is not available. 
SEQ The raw sequence, as originally defined in the FASTQ file. 
QUAL 
The Phred quality score for each base, as originally defined in 
the FASTQ file. 
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3.4.2.1. Converting SAM to BAM 
In a NGS pipeline, the main objective is to identify the set of genomic variants that are 
present in the studied samples. The first step needed is the conversion of the SAM file 
into a BAM file, because all the following steps require a BAM file as the input file. 
3.4.2.2. Removing possible duplicates 
After mapping our sequences with the reference sequence, we should to eliminate 
those reads that are duplicates, to avoid problems in the SNP calling for over-
representation of the reads. SAMtools allows removing those reads that can be PCR 
duplicates. 
3.4.2.3. Sorting and Indexing 
The next step is to sort and index the BAM file. Once we have sorted our BAM file, we 
can then index it creating a BAM index file which has the .bai extension.  
3.4.2.4. Filtering 
The called variants can be directly piped into the varFilter script that comes with 
SAMtools and filters for several parameters Examples of some of the parameters that 
can be applied are: 
-Q INT       minimum RMS mapping quality for SNPs 
-d INT     minimum read depth 
-D INT      maximum read depth 
-a INT       minimum number of alternate bases 
-w INT       SNP within INT bp around a gap to be filtered 
-W INT      window size for filtering adjacent gaps 
-1 FLOAT    min P-value for strand bias (given PV4) 
-2 FLOAT    min P-value for baseQ bias 
-3 FLOAT min P-value for mapQ bias 
-4 FLOAT    min P-value for end distance bias 
-e FLOAT     min P-value for HWE (plus F<0)         
-p print filtered variants 
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The filtered variants were not discarded immediately, however only variant that are 
marked as filtered in the VCF file will be taken into account for further analysis.  
3.4.2.5. Identifying Genomic Variants 
After all these steps, we can identify the genomic variants from our reads. It has to be 
done in two steps.  
The first step uses the SAMtools mpileup command to calculate the genotype 
likelihoods supported by the aligned reads in our sample. The mpileup command 
automatically scans every position supported by an aligned read, computes all the 
possible genotypes supported by these reads, and then computes the probability that 
each of these genotypes is truly present in the studied sample. For each position 
assayed, SAMtools computes all the possible genotypes, and then outputs all the 
results in a binary call format (BCF). 
The second step is uses the SAMtools bcftools command, which is also packaged 
with SAMtools, but located in the bcftools directory. The bcftools view command uses 
the genotype likelihoods generated from the previous step to call SNPs and indels. The 
outputs display all identified variants in the variant call format (VFC), the file format 
created for the 1000 Genomes Project and now widely used to represent genomic 
variants. 
3.4.2.6. The VCF format 
VCF files contain header lines, which begin with # or ## symbols, and data lines, which 
do not begin with a # symbol. The header contains important information, such as the 
name of the program that generated the file, the VCF format version number, the 
reference genome name, and information regarding individual columns within the file. 
Each data line is required to have eight mandatory columns, including CHROM 
reference, POSition within the chromosome, REFerence sequence, and ALT 
sequence. Directly after these eight columns there is a FORMAT column used to 
describe the format for all subsequent sample columns.  
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Within our VCF file, the FORMAT column is set to "PL". PL is defined as a list of 
Phred-scaled genotype likelihoods. DP indicates the position read depth and if in the 
FORMAT column there is PL, it indicates that all samples will include a list of 
genotypes likelihoods.  
As an example, in the case that the alignments column presents the cryptic string 
"64,178,0,66,147,60", the translation to the likelihood p-value automatically calculated 
with SAMtools are the following: 
Genotype Phred Scaled Score Likelihood p-value 
TT 64 3.981-07 
TG 178 2.512e-18 
GG 0 1.0 
TC 66 2.512e-07 
GC 147 1.995e-15 
CC 60 1.000e-06 
This indicates that the GG genotype is most probably the true genotype in the sample.  
 
3.4.3.  IGV 
 
The Integrative Genomics Viewer (IGV) (Robinson et al., 2011; Thorvaldsdottir et al., 
2013) is a high-performance desktop tool for interactive visual exploration of diverse 
genomic data. Even for very large data sets, IGV supports real-time interaction at all 
scales of genome resolution, from whole genome to base pairs. IGV has a user-friendly 
and intuitive interface. 
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3.5. VARIANT IDENTIFICATION 
 
To determine whether the sequence variants identified in the mitochondrial genomes of 
the schizophrenia patients had been previously described, predictive mtDNA 
haplogroups were determined using the Haplogrep software 
(http://haplogrep.uibk.ac.at/). Because of their unique population history, specific 
mtDNA haplogroups are identified in different geographic regions. Variant frequencies 
are different in different haplogroups. When identifying one or more rare variants from 
one individual, we have to check which haplogroup the individual belongs to. Then, we 
have to check the variants or mutations that are not linked to the haplogroup. There are 
several databases presenting mtDNA variants:  the Human Mitochondrial Genome 
Database (www.mitomap.org), the Human Mitochondrial Genome Polymorphism 
Database (www.giib.or.jp/mtsnp/index_e.shtml) and the alignment of 928 European 
sequences (http://www.broad.mit.edu/mpg/tagger/mito.php) are widely used. It is 
important to notice that MITOMAP, the December 11, 2013, included information from 
18363 GenBank sequences. When the genomic change was located in an encoding 
region, we used the MitoAnalyzer software 
(http://www.cstl.nist.gov/biotech/strbase/mitoanalyzer.html) and the mitowheel 
(http://mitowheel.org/mitowheel.html) to determine whether the variant triggered an 
amino acid change in the polypeptide sequence. 
 
 
HaploGrep is a web-based java application for determining the mtDNA haplogroups of 
a specific sequence. HaploGrep imports .hsd files – these are text files, having a 
sample id, range, haplogroup if known (otherwise empty space) and the 
polymorphisms separated by tabulators. The ranges itself are separated by “;”. The file 
contains the header information in the first row.  
To import our file, we have to click on the Open button. Then, the search process starts 
by clicking on “Find haplogroups”.  After this, a results window is shown. A Haplogroup 
column is presented, that suggests the haplogroup status.  The results can have three 
different colours: red, yellow and green, and the colour represent the quality of the 
haplogroup assignment. 
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- Red indicates that the haplogroup assignment is not very reliable. 
- Yellow indicates that the haplogroup assignment is more accurate but still 
there’s either sequence information lacking or many polymorphisms of the 
sample were not used for haplogroup assignment. 
- Green indicates that the haplogroup assignment is quite reliable, as a large 
proportion of the sample polymorphisms are explained by its haplogroup 
affiliation. 
 
By clicking on an entry on the results table, the lower part of the web-application will be 
filled with data, and mainly shows two areas: the information of the haplogroup in a 
tabular view and the corresponding graph showing the pathway from the rCRS. 
 
 
Figure 7. Information reported by Haploview 
 
 
In this web tool, for every sample’s haplogroup the following information is provided: 
 
1) The haplogroups sorted by their final rank. The highest scoring haplogroup is 
per default used as the suggested haplogroup 
 
2) The polymorphisms that are required by the current selected haplogroup. When 
a haplogroup-associated polymorphism is found in the sample, it is marked with 
yes, otherwise with no. 
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3) The remaining variants from the selected sample and the category which it 
belongs to. There are 4 categories: 
a. Hotspot: Mutation hotspots are 309.1C, 315.1C, 523-524d, 16182C, 
16183C, 16193.1C and 16519 
b. Local private mutation: mutation observed in this sample, but not 
associated with the selected haplogroup. 
c. Global private mutation: mutation never observed in Phylotree, probably 
due to inconsistent alignments, phantom mutations or point 
heteroplasmies. Phylotree is a phylogenetic tree of global human 
mitochondrial DNA variation, based on both coding- and control-region 
mutations, and including haplogroup nomenclature. This mtDNA tree is 
meant as a framework for evolutionary anthropologists, medical 
geneticists, genealogists and forensic geneticists (van Oven and 
Kayser, 2009). 
 
d. Out of range: polymorphism lies outside the indicated range. 
 
4) The graph showing the pathway from the rCRS to the currently selected 
Haplogroup. There are different colour-coding for the polymorphisms: 
 
 
3.6. PATHOGENICITY PREDICTION 
 
There are some criteria that suggest that a novel base change is pathogenic. After 
confirm that the variant is not a known polymorphism, it is important to check if the 
base change is affecting a site that is conserved during evolution. 
To assess these possible implications of the variants detected, it is needed an in silico 
analysis by the utilization of computational algorithms, databases and online resources 
for the prediction of pathogenicity of missense variants. Some of these resources are 
tools as mtSNP (http://mtsnp.tmig.or.jp/cgi-bin/mtsnp/snpSearch/snpSearchEnglish.cgi) 
to determine the Grantham index of those variants that have been reported yet, SIFT 
and Polyphen that gave us a probability of pathogenicity of the aminoacidic change and 
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Align-GVGD that provides a classification of the aminoacid conservation (Grantham 
Score).  
Protein sequence conservation analysis at a specific position is the first step to infer 
functional importance of an amino acid residue. The protein sequence containing the 
amino acid of interest should be used as a query for analysis using the NCBI protein 
website. We can Use ClustalW2—Multiple Sequence Alignment tool 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) for multiple sequence alignment. 
The SIFT algorithm (sorting intolerant from tolerant) (http://sift.jcvi.org) is mainly based 
on sequence homology and the physical properties of amino acids to make predictions 
about protein function. It can be used to predict the likely effect of a non-synonymous 
substitution on protein function. 
The PolyPhen (from polymorphism phenotyping) uses sequence-based features and 
structural information for characterizing the substitution to make predictions about the 
structure and function of the new protein. It is a structure-sequence-based amino acid 
substitution prediction method. The current version is PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2). It uses the data available in 
UniProtKB/UniRef100 and is based on conservation, protein folding, and crystal 
structure. This analysis classifies variants as likely benign, possibly damaging, or 
probably damaging when predicting pathogenicity. 
 
With the mtSNP tool we can know the Grantham score of each variant that has been 
previously submitted, however, to know this score in the rest of the variants, we use 
ALIGN GVGD tool. Align-GVGD is a freely available, web-based program that 
combines the biophysical characteristics of amino acids and protein multiple sequence 
alignments (hand-made using Uniprot, selecting all the species that mtSNP tool uses to 
predict the Grantham score) to predict where missense substitutions in genes of 
interest fall in a spectrum of grades of clinical significance.  
Align-GVGD is an extension of the original Grantham differences to multiple sequence 
alignments and true simultaneous multiple comparisons.   
The biochemical variation at each alignment position is converted to a Grantham 
Variation score (GV). The difference between the properties of the wild-type amino acid 
and those of the amino acid variant being assessed are calculated and a Grantham 
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Difference score is generated (GD). These values are used as a measure of how likely 
the substitution is to be deleterious or neutral on a classification spectrum. The 
prediction classes form a spectrum (C0, C15, C25, C35, C45, C55, C65) with C65 most 
likely to interfere with function and C0 least likely (Tavigtian, SV et al, 2006).  
None of these softwares have been clinically validated according to mitochondrial 
disorders because these applications are based on nuclear-encoded proteins. Proteins 
that are mtDNA-encoded have a different evolutionary conservation and there should 
be a source of errors when using these types of prediction tools. Bioinformatics 
prediction tools may be valuable as screening tools for identifying alleles of high 
pathogenicity for molecular and disease association studies. However, because the 
error rates in both nuclear and mitochondrial predictions are still high, current 
algorithms do not supplant the need for in vitro or in vivo studies. 
However, we can take into account those variants that are in a region that is 
functionally important. This essentially means anywhere in the tRNA genes, and rRNA 
genes, and not only considering those that cause an amino acid change in the protein 
encoding genes. 
 
3.7. STATISTICAL ANALYSIS 
 
One of the objectives of this study is to identify whether schizophrenia patients present 
a higher number of variants in the mitochondrial DNA than control subjects. After the 
identification of all the variants that doesn’t characterize the haplotype of a sample, we 
decided to infer whether there is an increased number of variants in cases than in 
controls, which  could be related with the disease. With this goal, we applied an 
unpaired Wilcoxon test, which is a nonparametric alternative to the two-sample t-test 
when data do not follow a normal distribution and the sample size is small. .  
Statistical analyses were performed using R language.  
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4. RESULTS AND CONCLUSIONS 
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4.1. RESULTS OF THE VARIANT IDENTIFICATION 
 
In this study, the PGM equipment was used to sequence 93 mitochondrial genomes 
from 93 different samples. The use of barcoded adaptors allowed simultaneous 
sequencing of multiple samples with the PGM.  
 
After applying all the steps of the bioinformatic analysis, and check each sample in 
Haplogrep to determine the haplogroup of each sample analyzed, we obtain a list of 
variants of each sample that doesn’t define its haplogroup and also some variants that 
doesn’t appear in Phylotree but they can be found in Mitomap or in the bibliography. 
We also obtain a list of variants that could not be found in any resource. According to 
these variants, they have not been submitted yet as a haplogroup variant, as an 
unclassified variant or as pathogenic variant. There are a lot of parameters that have to 
take into account to accept or discard a new variant. To determine the list of variants 
that present each sample and also to determine which of these variants can be 
candidates for additional studies, different analysis thresholds were established: 
 
- A Phred-like quality score of the called genotype (Q call). The Q call established 
as a threshold was a value larger than 200 to detect all the homoplasmic 
variants. This threshold allows us to have a high reliability in the results. We 
detect also that all the variants with a low Q call value were heteroplasmic 
variants or artefacts of the technique. It is needed to use IGV viewer to 
determine whether those variants with a Qcall lower than 200 were definitively 
heteroplasmic variants. However, it is important to check them with Sanger 
Sequencing to definitively prove that it is a new variant. Moreover, some of the 
indels with a Qcall larger than 200 were checked with IGV viewer to determine 
the possibility of being a homopolimer artefact, that is, stretches of DNA 
containing the same base.  
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Figure 8. Example of the P029 variant m.15326A>G. In this case we can conclude that this variant is in 
homoplasmy. 
 
 
Figure 9. Example of the P029 variant c.8936T>A. This variant have been discarded because of its 
Qcall<200 and probably is a variant in heteroplasmy. 
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- Depth of coverage. We also establish a depth of coverage larger than 30X. This 
is an arbitrary value, however looking at the bibliography we can see that is a 
minimum value of coverage to have reliable results (Wang J, et al. 2012). 
 
- The percentage of cases with the same variant. We proceed with the 
elimination of known polymorphisms and variants present in more than 1% of 
the cases (an arbitrary value found in the Bibliography as a correct value as the 
definition of rare mtDNA variants calculating a frequency of 93:1=1% ) (Wang J, 
et al. 2012). Of those variants that have never been described, we only list 
those that are in less than 10% of the samples, assuming that those that are in 
a higher percentage can be artefacts of the technique, for example the deletion 
in the position 9546 that can be observed in the vast majority of the samples. 
 
 
Table 3 (Supplementary files) presents each variant with the average of the Q call, the 
number of cases presenting the variants and whether they have been reported before. 
As we can see, some of the variants detected had never been submitted before. Those 
variants that weren’t in the public databases were candidates for further analyse of its 
putative pathogenicity.  
The known mutations and novel variants identified in the study are listed in table 4 and 
5 (Supplementary files). The classification of each sample on its haplogroup, variants 
that don’t appear in the haplogroup (i.e. variants that belong to another haplogroup, 
variants that have already been described and variants never described before), and 
the Genbank frequency are also presented. 
We can observe that there are some variants that have not been previously reported. 
Some of the polymorphisms that have been described are related with a mitochondrial 
disease, like m.3310C>T that have been related with diabetes mellitus type II patients 
and with heart disease (Hattori Y, et al.2005). 
Interestingly, there are twelve variants that have not been described before. Alignment 
of mitochondrial sequences that include different mitochondrial haplogroups, revealed 
synonymous as well as non-synonymous sequence variation that may affect 
mitochondrial protein function. In table 6 we can see the Polyphen prediction and also 
the Grantham Value of the missense variants.  To know the possible implications of the 
mtDNA variant at the protein level, these variants have been submitted to in silico 
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analysis to obtain the Grantham score. Using Grantham score (Grantham, 1974), 
which categorize amino acid substitutions into classes of increasing chemical 
dissimilarity, 16 out of the 33 non-synonymous mutations were designated as 
conservative (score 0 to 50), 15 moderately conservative (score 51 to 100), and 2 
moderately-radical (score 101 to 150) substitutions, according to the proposed 
classification (Li et al. 1984).  
Several of the sequence variations were observed in some, but not all haplogroups, 
suggesting relatively early mutation events in mitochondrial evolution, whereas other 
variants segregated within haplogroups, suggesting relatively more recent mutation 
events, e.g. 1182C variation was found in samples C014, P007 and P025, all of them 
belonging to the U2d haplogroup. 
 
 
Table 6. Variants not reported before 
VARIANT 
CHANGE 
EFFECT 
LOCUS 
ALIGN-GVGD 
PREDICTION 
POLYPHEN 
PREDICTION 
2861G 
 MT-RNR2 (rRNA) 
  
3106insC 
 MT-RNR2 (rRNA)   
3107T 
 MT-RNR2 (rRNA)   
5818T 
 MT-TC (tRNA)   
8209T aa 209 SYN MT-CO2   
8863A p.V113M MT-ATP6 48.95 (C0) PROBABLY DAMAGING 
9506T aa 100 SYN MT-CO3   
11812C aa 351 SYN MT-ND4   
11926T aa 389 SYN MT-ND4   
12568T aa 78 SYN MT-ND5   
13338A p.F334L MT-ND5 354 (C0) PROBABLY DAMAGING 
14593insC aa 27 SYN MT-ND6   
 
Only two non-reported variants were predicted as probably damaging, both detected in 
control samples. These were a valine to methionine substitution in the protein encoded 
by MT-ATP6 and a phenylalanine to leucine in the protein encoded by MTND5, a core 
subunit of the mitochondrial respiratory chain NADH dehydrogenase (Complex I) that is 
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believed that belong to the minimal assembly required for catalysis. Complex I 
functions in the transfer of electrons from NADH to the respiratory chain.  
 
Furthermore, we have also identified novel not missense variants. Because of there is 
no change in the amino acid sequence they were not considering for further study. 
However, it can be useful to develop a directed study to analyze the presence of these 
variants in a huge amount of patients and controls and also to develop functional 
studies of all these variants that are located in important regions like the control region 
where we cannot infer whether the change of this variant modify the functionality of this 
non-coding region. 
 
 
4.2. RESULTS OF THE CASE-CONTROL STUDY 
 
We apply the Wilcoxon Test to determine whether the schizophrenia patients present a 
distinct number of variants compared to the controls. This test assesses whether the 
distribution of values in two samples differ or not. Descriptive statistics and the results 
of the statistical test are shown in Table 7. In a first analysis we take into account only 
those variants that are not involved in defining the haplogroup for each participant. The 
differences in the number of variants present in cases (N=51; =0.9444, SD=1.07) and 
control subjects (N=33;  = 0.8684, SD=1.0698) are not significant (W=981, p=0.706).  
We repeat this analysis but taking into account all the variants in each sample, in cases 
(N=214; =3.019, SD=2.4378) and controls (N=137; =2.737, SD=2.511425), that 
doesn’t define the haplogroup where it belongs to, and the result is also not statistically 
significant (W= 925.5; p= 0.422).  
In conclusion, we don’t identify evidences of any difference between patients and 
controls in the number of variants present in their mtDNA molecules. However, this 
result should be taken carefully because probably the sample size of this study is 
insufficient to determine whether there is an association between the number of 
variants and the presence of the disease.  
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Table 7. Descriptive statistics and  the Wilcoxon Test for comparing the number of variants in  the two 
groups of individuals.  
SAMPLES QUANTILES                        VARIANTS 
  NOT 
ASSOCIATED TO 
ANY HAPLOTYPE 
ALL THE VARIANTS (INCLUDED 
THOSE THAT DEFINE OTHERS 
HAPLOTYPES) 
Min 0.0000 0.000 
1st Qu. 0.0000 1.000 
Median 1.0000 2.000 
Mean 0.8684 2.737 
3rd Qu 1.0000 4.000 
Max 4.0000 10.000 
 
CONTROLS 
 
N=38 
sd 1.0698 2.511425 
 N 33 137 
 
   
Min 0.0000 0.000 
1st Qu. 0.0000 1.000 
Median 1.0000 3.000 
Mean 0.9444 3.019 
3rd Qu 1.7500 4.000 
Max 4.0000 12.000 
PATIENTS 
 
N=55 
sd 1.0714 2.4378 
 N 51 214 
981 925.5 
      W 
               p-value 0.7058 0.4218 
 
 
Figure 10. Boxplot of the comparison of the number of variants that present controls and samples. In blue 
we can see the boxes corresponding only to the number of variants excluding those that define another 
haplotype. In green we take into account all those variants that present the samples (excluding those that 
define their haplotype). 
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We also make this analysis taking into account the region of the mitochondrial DNA 
where the mutation is located. The mtDNA can be divided into two distinct important 
regions: the control region, also known as the D-loop and the coding region. We divide 
the variants detected into these two locations and perform the statistical analysis 
comparing the presence of variants between cases and control samples. The number 
of variants in the coding region in control subjects (N=68; X=1.789, SD=2.0816) and 
patients (N=98, X=1.782, SD=1.8628) is not statistically different. We also analyze the 
difference of the presence of variants in the control region between controls (N=32, 
X=0.8421, SD=0.8229) and patients (N=64, X=1.109, SD=0.8229) and neither is a 
statistically difference between these groups (W=876, p=0.1586). However, we 
observe that the presence of variants in the coding region in patients is slightly higher 
than in controls.  
To determine if there are differences of the number of variants between the two mtDNA 
regions of the same group of individuals, we apply a paired Wilcoxon Test and in this 
case we observe that there are significant differences in both groups of samples, that is 
that the number of variants observed is significantly higher in de coding region in cases 
(V=499, p=0.02361) and in control subjects (V=320, p=0.006827). 
 
 
 
 
 
Figure 11. Boxplot of the comparison of the number of variants located in two  
main important regions of the mtDNA.  
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Table 8. Statistical results of the Wilcoxon Test comparing the number of variants of the diferent mtDNA 
regions that present the two groups of individuals and the quantile values of the boxplot. 
SAMPLES QUANTILES MtDNA REGION  
  
CODING 
 REGION 
CONTROL 
REGION 
 
Min 0.000 0.0000 
1st Qu. 0.000 0.0000 
Median 1.000 1.0000 
Mean 1.789 0.8421 
3rd Qu 3.000 1.0000 
Max 8.000 3.0000 
 
CONTROLS 
 
N=38 
sd 2.081552 0.8228597 
V = 320 
p = 0.006827 
 N          68           32 
 
    
Min 0.000 0.000 
1st Qu. 0.000 0.000 
Median 2.000 1.000 
Mean 1.782 1.109 
3rd Qu 2.500 2.000 
Max 9.000 4.000 
PATIENTS 
 
N=55 
sd 1.862803 0.936358 
V = 499 
p = 0.02361 
 N          98          61 
1002.5 876  
      W 
               p-value 0.7361 0.1586  
 
 
 
 
4.3. CONCLUSIONS 
 
We have studied the entire mtDNA of 55 schizophrenia subjects with a matrilineal 
transmission pattern of the illness to test the hypothesis that mutations present in their 
mitochondrial genomes contribute to the genetic basis of the illness and in 38 control 
subjects. We found considerable sequence diversity. When we compared the mtDNA 
of the patients with the revised Cambridge sequence, we found 147 homoplasmic 
variants that don’t define the haplotype of the sample (they can be variants that define 
other haplogroups or other polymorphisms, rare variants or mutations). All variants 
were distributed along the mitochondrial genome and did not accumulate in a specific 
region. Of the 147 variants, twelve have not been previously reported and two of them 
were non-synonymous substitutions but both where only detected in controls. We also 
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found some variants that have been reported before and it can be hypothesized that 
they can be involved in the increased susceptibility to schizophrenia, e.g. m.4136A>G 
with a Grantham score of 194 and m.3368T>C with a Grantham score of 81. There are 
also some samples (e.g. patient P042) that have a larger number of missense variants; 
this is an important issue to take into account because, as we mentioned before, the 
susceptibility of mitochondrial disorders is not only due to the presence of one variant 
but to the accumulation of several variants. 
The other variants found are located in the MT-RNR2 region (that codifies rRNA), MT-
CO2, MT-CO3, MT-ND4, MT-ND5 and MT-ND6. We have observed that the number of 
synonymous variants is larger than the number of missense variants. This can be 
explained by the purifying selection that perhaps acts against amino acid changes in 
the protein-coding genes (Lawrie DS, et al. 2013). The vast majority of variants found 
during our study are synonymous variants or changes located in non-coding regions. It 
is important to consider that these variants can be also important for the functionality 
and replication of the mitochondria. 
 
Nevertheless, after analyze the differences between cases and controls; we realize that 
there are no statistical differences in the presence of variants between the two groups 
or the different mitochondrial regions. This result can be due because of the small size 
of our control-case study; consequently a larger sample size study is needed to 
determine if there is a significant difference between the two populations. 
 
 
 
4.4. LIMITATIONS OF THE STUDY AND FUTURE WORK 
 
 
One of the most important limitations of this project was the lack of sequences obtained 
by Sanger sequencing. The resulting list of variants should be compared with the 
variants detected by Sanger Sequencing of the exact samples. As we mentioned, it is 
known that a 500X coverage in the NGS is needed to determine the heteroplasmic 
level. To further determine the correct threshold that we have to apply to detect 
heteroplasmic variants, an incoming step performing a Next Generation Sequencing 
with a 500X coverage and a Sanger Sequencing of several samples are needed to 
validate the different variants candidates to be heteroplasmic variants. 
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In a following step, some important things have to be done: 
 
- An R package, homologous to ANNOVAR (that provides variant annotation), 
linked to haplogrep, to establish the haplogroup of each sample, and all this 
variants susceptible to be a pathogenic mutation, also looking at the SIFT and 
Polyphen tools. Since the end of 2013, in the ANNOVAR package there is also 
the possibility to annotate mitochondria variants. However there are several 
important caveats as the Reference Sequence used by ANNOVAR is not the 
correct sequence because the UCSC’s hg19 assembly used the old version of 
the mitochondria genome. The problem is whether we align our data against the 
Reference sequence (NC_012920), we cannot really annotate our variants 
using UCSC’s gene definition. Now, with ANNOVAR we have to look at those 
variants that align together with chrM of the UCSC 
 
- To test matrilineal relatives. Targeted sequence analysis of the patient’s mother 
and other matrilineal relatives is recommended to be done to determine if the 
variants detected are definitely matrilineal inherited. When a variant is 
homoplasmic in asymptomatic matrilineal adult relatives and is not 
cosegregating with the disease phenotype, then that variant, by itself, is unlikely 
to be the primary cause of the clinical symptoms. If a variant is absent or at low 
level of heteroplasmy in asymptomatic matrilineal relatives or is cosegregating 
with disease phenotype, then this variant may be pathogenic.  
 
- Additional studies, including mitochondrial functional studies may be needed to 
further try to clarify the clinical significance of the variants found, including 
missense variants and also those non-codifying variants but nevertheless they 
can be important in any function like these variants located in the control region. 
 
In conclusion, these results need to be validated by Sanger Sequencing and replicated 
in many more samples to further determine the validity of the obtained results. It would 
also be interesting to analyse in other case-control studies some of the novel variants 
found (after confirm their presence by Sanger). 
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Table 3. List of variants detected with a Q call>200 
VARIANT QCALL AVERAGE SAMPLES 
REPORTED 
PREVIOUSLY 
93G 222 P014 Yes 
143A 222 P020 Yes 
146C 222 P052 Yes 
152C 222 C045,P008,P012,P015,P042 Yes 
186A 222 P021 Yes 
195C 222 P015,P036 
YES (disease 
associated?) 
204C 222 P027 Yes 
207A 222 P027 Yes 
234G 222 C038 Yes 
239C 222 P059 Yes 
295T 204 C039 Yes 
309.1CT 208 P002,P005,P020,C001,C030,C048 Yes 
524.1AC 214 P007,P025,P045,C029,C014,C032, C036 Yes 
534T 222 P037 Yes 
709A 222 C014,C015, P007, P025, P052 Yes 
729C 222 P028, 
Yes (disease 
associated?) 
1027G 222 P002 
Yes(disease 
associated?) 
1189 222 C039 Yes 
1192T 222 P035 
Yes(disease 
associated?) 
1694C 222 P056 Yes 
2501T 222 P059 Yes 
2558G 222 P039 Yes 
2861G 222 P043 No 
3010A 222 P009 Yes 
3083C 222 P042 Yes 
3084G 222 C045 Yes 
3106.1C 214 P020 No 
3107T 214 C032,C041 No 
3310T 222 P026 Yes (disease 
associated?) 
3368C 222 P010 Yes 
3391A 222 P021 Yes 
3540C 222 C039 Yes 
3774G 225 P039 Yes 
4029T 222 C001,C040 Yes 
4136G 222 C036,P031 Yes 
4619C 222 C048 Yes 
5046A 222 P065 Yes 
5585A 222 P023 Yes 
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VARIANT QCALL AVERAGE SAMPLES 
REPORTED 
PREVIOUSLY 
5818T 222 C021 No 
5960T 222 P056 Yes 
6095G 222 C036 Yes 
6182A 209 P062 Yes 
6212G 222 P022, Yes 
6249G 222 C048 Yes 
6503G 222 P007,P025,C014 Yes 
6590C 222 P050 Yes 
6734A 222 P040 Yes 
6908C 222 P062 Yes 
7220C 222 P036 Yes 
7280T 222 P022 Yes 
7317G 222 C028 Yes 
7468T 222 P022 Yes 
7775A 222 C039 Yes 
7830A 222 P066 Yes 
8020A 222 C039 Yes 
8209T 222 C047 No 
8269A 222 C040,C001 Yes 
8281-8289del 214 P002 Yes 
8475T 222 P064 Yes 
8513T 222 C021 Yes 
8639C 222 P046 Yes 
8701G 222 P042 Yes 
8706G 222 C028 Yes 
8838A 222 C028 Yes 
8863A 222 C032 No 
9182A 222 P038,P065 Yes 
9490T 222 P054 Yes 
9506T 222 P018 No 
9899C 222 P015 Yes 
9909C 222 P042 Yes 
9966A 221 C043 Yes 
10199T 222 P050 Yes 
10248C 222 C025 Yes 
10398G 222 P055 Yes 
10544T 222 P056 Yes 
11063T 222 P035 Yes 
11404G 222 P032 Yes 
10463C 222 P053 Yes 
11653G 222 C013 Yes 
11654G 222 P042 Yes 
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VARIANT QCALL AVERAGE SAMPLES 
REPORTED 
PREVIOUSLY 
11812C 222 P007, P025, C014 No 
11836G 222 P040 Yes 
11914A 222 C048, P043 Yes 
11926T 222 C032 No 
11971T 222 P035 Yes 
12103A 222 C006 Yes 
12373G 222 P042 Yes 
12568T 225 P039 No 
12582G 222 P004 Yes 
12612G 222 P009 Yes 
12684A 222 P029 Yes 
12945C 222 P004 Yes 
13105G 222 P042,P062, Yes 
13135A 222 C001, C040 Yes (disease 
asssociated?) 
13161C 222 C033 Yes 
13191C 222 P035 Yes 
13230T 222 C045 Yes 
13242G 222 C005 Yes 
13338A 222 C006 No 
13359A 222 P027 Yes 
13464T 225 P026 Yes 
13557G 222 C039 Yes 
13575T 225 P047 Yes 
13608C 222 C048 Yes 
14002G 222 P043 Yes 
14003T 222 C006 Yes 
14016A 111 P028 Yes 
14034C 222 P002 Yes 
   
 
14178C 222 P066 Yes 
14259A 222 P054 Yes 
14544A 204 P010,P064 Yes 
14572G 222 P046 Yes 
14593.1C 222 P053 No 
14755G 222 P066 Yes 
14869A 222 P038 Yes 
15257A 222 P026 Yes 
15514C 222 C001, C040 Yes 
14861A 222 P066 Yes 
15916C 222 P035 Yes 
15924G 222 C048,P018 Yes 
15927A 222 P025 Yes(related with 
disease?) 
ANALYSIS OF THE MITOCHONDRIAL DNA OF SCHIZOPHRENIA PATIENTS BY NGS 
 
52 
 
VARIANT QCALL AVERAGE SAMPLES 
REPORTED 
PREVIOUSLY 
15977T 222 P055 Yes 
15984C 222 P025 Yes 
16042A 222 P050 Yes 
16092C 222 P032 Yes 
16093C 222 P014,P045,C038,C043 Yes 
16111T 222 P032,P045 Yes 
16129A 222 C031 Yes 
16162G 222 C001,C040 Yes 
16163G 222 P015 Yes 
16171G 222 P058 Yes 
16180G 218 P047 Yes 
16183d 214 P040 Yes 
16193T 222 C036 Yes 
16189d 202 P015,P055 Yes 
16241G 222 P040 Yes 
16249C 203 P047 Yes 
16261T 222 P052 Yes 
16270T 222 P038,P065 Yes 
16286A 191 P002 Yes 
16290T 222 C041 Yes 
16298C 222 P031 Yes 
16311C 222 P004,P038,P065 Yes (disease 
associated?) 
16319A 222 P011 Yes 
16342C 222 P042 Yes 
16362C 222 C026,P036,P001 Yes 
16519C 222 C001, C010, P044 Yes 
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Table 4. Variants (that doesn’t define the haplogroup of the sample) identified in the 38 controls, sequenced by NGS. 
Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
309 CT insertion MT-DLOOP    6 - 
4029 C > T MT-ND1 241   2 2 
8269 G > A MT-CO2 228   2 252 
13135 G > A MT-ND5 267 A > T 58 (185-C0) 2 194 
C001 H1e1a 
15514 T > C MT-CYB 256   2 110 
  
16162 A > G MT-DLOOP    2 223 
  
16519 T > C MT-DLOOP    3 11617 
200 A > G MT-DLOOP    1 447 
C005 T2c1D1a 
13242 A > G MT-ND5 302   1 1 
4796 C > T MT-ND2 109   1 7 
10550 A > G MT-ND4L 27   1 915 C006 U5a1+!16192 
12103 C > A MT-ND4 448   1 4 
  
13338 C > A MT-ND5 334 F > L 354 (C0) 1  
  
14003 C > T MT-ND5 556 T > I 89 (161-C0) 1 6 
  
14527  A > G MT-ND6 48   1 11 
  
14893 A > G MT-CYB 49   1 32 
  
14971 T > C MT-CYB 75   1 34 
  
16278 C > T MT-DLOOP    1 1845 
C007 U1a1b 523-524 delAC MT-DLOOP    11  
C008 T2b6a         
C009 H2a5a1         
13215 T > C MT-ND5 293   1 82 
16216 A > G MT-DLOOP    1 17 C010 V1a 
16519 T > C MT-DLOOP    3 11617 
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
C012 H10b 9448 A > G MT-CO3 81 Y > C 194 (C65) 2 5 
11440 G > A MT-ND4 227   1 127 
11653 A > G MT-ND4 298   1 149 
15737 G > A MY-CYB 331 D > N 23.01 (C0) 1 3 C013 J1c3e1 
16153 G > A MT-DLOOP    1 175 
524 insCA MT-DLOOP    7 9 
709 G > A MT-RNR1    5 2404 
930 G > A MT-RNR1    3 419 
4164 A > G MT-ND1 286   3 130 
6503 A > G MT-CO1 200   3 4 
10343 C > T MT-ND3 95   3 12 
11812 A > C MT-ND4 351   3  
12127 G > A MT-ND4 456   3 44 
16266 C > T MT-DLOOP    3 204 
C014 U2d 
16525 A > G MT-DLOOP    2 9 
C015 U4a1b 709 G > A MT-RNR1    5 2404 
C016 R0a4         
12681 T > C MT-ND5 115   1 29 
C019 J1c3 
16213 G > A MT-DLOOP    1 185 
523-524 AC > del MT-DLOOP    11  
5567 T > C MT-TW    1 17 C020 H5a1 
7570 A > G MT-TD    1 4 
5818 C > T MT-TC  tRNA  1  
8513 C > T MT-ATP8 50 P > S 214 (C0) 1 2 C021 H1 
10253 T > C MT-ND3 65   1 8 
FINAL MASTER PROJECT_MARTA RODRIGUEZ BALADA 
 
 
55 
 
Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
C023 H1j1         
7269 G > A MT-CO1 456 V > M 29 (C0) 1 28 
10248 T > C MT-ND3 64   1 20 C025 H1 
13188 C > T MT-ND5 284   1 111 
C026 J2b1a1 16362 T > C MT-DLOOP    3 3089 
C027 H1ba         
7317 A > G MT-CO1 472 I > V 29 (C0) 1 1 
8706 A > G MT-ATP6 60   1 10 C028 HV0+195 
8838 G > A MT-ATP6 104   1 40 
C029 K1a4a1e 524 insCA MT-DLOOP    7 9 
C030 I1a1b 309 insCT  MT-DLOOP    6 - 
C031 K1a4a1 16129 G > A MT-DLOOP    1 2159 
524 insCA MT-DLOOP    7 9 
3107 N > T MT-RNR2  rRNA  2  
8863 G > A MT-ATP6 113 V > M 49 (C0) 1 2 C032 K1a+195 
11926 A > T MT-ND4 389   1  
9300 G > A MT-CO3 32 A > T 58 2 84 
13161 T > C MT-ND5 275   1 12 
13958 G > C MT-ND5 541 G > A 60 (209-C0) 1 68 C033 U5b2b 
16296 C > T MT-DLOOP    1 388 
C035 H4a1a2         
524 insCA MT-DLOOP    7 9 
4136 A > G MT-ND1 277 Y > C 194 2 23 C036 H4a1a1a 
6095 A > G MT-CO1 64   1 2 
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
  
16193 C > T MT-DLOOP     221 
C037 H3q         
  
234 A > G MT-DLOOP    1 80 
C038 J1c2e2 523-524 delAC MT-DLOOP    11  
  
16093 T > C MT-DLOOP    4 984 
295 C > T MT-DLOOP    1 837 
1189 T > C MT-RNR1  rRNA   749 
3540 T > C MT-ND1 78   1 15 
7775 G > A MT-CO2 64 V > I 29 (C0) 1 24 
8020 G > A MT-CO2 145   1 213 
13557 A > G MT-ND5 407   1 6 
C039 HV 
15904 C > T MT-TT  tRNA  1 286 
  
        
4029 C > T MT-ND1 241   2 2 
8269 G > A MT-CO2 228   2 252 
13135 G > A MT-ND5 267 A > T 58 2 194 
15514 T > C MT-CYB 256   2 110 
C040 H1e1a 
16162 A > G MT-DLOOP    2 263 
524 insCA MT-DLOOP    7 9 
3107 N > T MT-RNR2  rRNA  2  C041 U4a1 
16290 C > T MT-DLOOP    1 606 
C042 H10b 9448 A > G MT-CO3 81 Y > C 194 (C65) 2 5 
9966 G > A MT-CO3 254 V > I 29 1 117 
C043 H1e1a1 
16093 T > C MT-DLOOP    4 984 
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
152 T > C MT-DLOOP    6 3807 
3084 A > G MT-RNR2  rRNA  1 4 C045 H1bf 
13230 C > T MT-ND5 298   1 3 
C047 H5a 8209 C > T MT-CO2 209   1  
          
309 insCT  MT-DLOOP    6 - 
4619 T > C MT-ND2 50   1 3 
6249 G > A MT-CO1 116 A > T 58 (104-C0) 1 33 
7283 T > C MT-CO1 460    110 
11914 G > A MT-ND4 385   2 2063 
C048 N1b1a2 
13608 T > C MT-ND5 424   1 7 
C049 U2e1a1 15924 A > G MT-TT  tRNA  2 645 
  
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANALYSIS OF THE MITOCHONDRIAL DNA OF SCHIZOPHRENIA PATIENTS BY NGS 
 
58 
 
 
Table 5. Variants (that doesn’t define the haplogroup of the sample) identified in 55 cases, sequenced by NGS 
Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
9300 G > A MT-CO3 32 A > T 58 2 84 
13635 T > C MT-ND5 433   1 45 
16293 A > G MT-DLOOP    1 393 
P001 U6a1a1 
16362 T > C MT-DLOOP    3 3089 
309 insCT MT-DLOOP    6 - 
1027 A > G MT-RNR1  rRNA  1 5 
8281-8289 del MT-NC7    1 - 
9804 G > A MT-CO3 200 A > T 58 1 56 
14034 T > C MT-ND5 566   1 79 
P002 U4a1 
16286 C > A MT-DLOOP    1 10 
12582 A > G MT-ND5 82   1 5 
12945 T > C MT-ND5 203   1 4 
16294 C > T MT-DLOOP    1 1743 
P004 U5a1b1 
16311 T > C MT-DLOOP    3 3659 
P005 T2b3b 309 insCT  MT-DLOOP    6 - 
524 insCA MT-DLOOP    7 9 
709 G > A MT-RNR1    5 2404 
930 G > A MT-RNR1    3 419 
4164 A > G MT-ND1 286   3 130 
6503 A > G MT-CO1 200   3 4 
10343 C > T MT-ND3 95   3 12 
11812 A > C MT-ND4 351   3  
P007 U2d 
12127 G > A MT-ND4 456   3 44 
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
16266 C > T MT-DLOOP    3 204 
152 T > C MT-DLOOP    6 3807 
P008 K1a1b1 
3736 G > A MT-ND1 144 V > I 29 1 42 
3010 G > A MT-RNR2  rRNA  1 3108 
P009 T1a1+!152 
12612 A > G MT-ND5 92   1 924 
523-524 delAC MT-DLOOP    11  
3368 T > C MT-ND1 21 M > T 81 1 6 P010 H5a1 
14544 G > A MT-ND6 44   2 56 
P011 U5b1f 16319 G > A MT-DLOOP    1 1059 
P012 H1j1 152 T > C MT-DLOOP    6 3807 
P013 H1bx         
93 A > G MT-DLOOP    1 427 
P014 K1a+195 
16093 T > C MT-DLOOP    4 984 
152 T > C MT-DLOOP    6 3807 
195 T > C MT-DLOOP    2 3688 
9899 T > C MT-CO3 231   1 217 
16163 A > G MT-DLOOP    1 258 
P015 T 
16189 del MT-DLOOP    2 971 
P016 H6a1b2         
9506 C > T MT-CO3 100   1  
P018 H1j 
15924 A > G MT-TT  tRNA  2 645 
P019 U5b3         
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
143 G > A MT-DLOOP    1 356 
309 insCT  MT-DLOOP    6 - P020 W6a 
3106 insC MT-RNR2  rRNA  1 - 
186 C > A MT-DLOOP    1 220 
P021 H1i 
3391 G > A MT-ND1 29 G > S 56 1 26 
6212 A > G MT-CO1 103   1 3 
7280 C > T MT-CO1 459   1 7 P022 K1a+195 
7468 C > T MT-TS1  tRNA  1 5 
P023 H1e 5585 G > A MT-NC3  Non-coding  1 90 
P024 H27         
524 insCA MT-DLOOP    7 9 
709 G > A MT-RNR1    5 2404 
930 G > A MT-RNR1    3 419 
4164 A > G MT-ND1 286   3 130 
6503 A > G MT-CO1 200   3 4 
10343 C > T MT-ND3 95   3 12 
11812 A > C MT-ND4 351   3  
12127 G > A MT-ND4 456   3 44 
15927 G > A MT-ATT   tRNA 1 205 
15984 T > C MT-ATT   tRNA 1 3 
16266 C > T MT-DLOOP    3 204 
P025 U2d 
16525 A > G MT-DLOOP    2 9 
3310 C > T MT-ND1 2 P > S 158 (C0) 1 8 P026 K1a4a1 
13464 C > T MT-ND5 376   1 1 
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
15257 G > A MT-CYB 171 D > N 23 1 242 
204 T > C MT-DLOOP    1 991 
207 G > A MT-DLOOP    1 814 P027 T2b 
13359 G > A MT-ND5 341   1 60 
523-524 delAC MT-DLOOP    11  
729 T > C MT-RNR1   rRNA 1 1 P028 H3 
14016 G > A MT-ND5 560   1 70 
523-524 delAC MT-DLOOP    11  
P029 H1c 
12684 G > A MT-ND5 116     
4136 A > G MT-ND1 277 Y > C 194 2 23 
P031 V+!16298 
16298 T > C MT-DLOOP    1 960 
11404 A > G MT-ND4 215   1 38 
16092 T > C MT-DLOOP    1 234 P032 H1e5 
16111 C > T MT-DLOOP    2 486 
P033 H1j1         
P034 U6a1a1         
1192 C > T MT-RNR1    1 3 
11063 C > T MT-ND4 102   1 3 
11971 C > T MT-ND4 404   1 4 
13191 T > C MT-ND5 285   1 21 
P035 U6a1 
15916 T > C MT-TT  tRNA  1 10 
195 T > C MT-DLOOP    2 3688 P036 H5a1c1a 
523-524 delAC MT-DLOOP    11  
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
7220 T > C MT-CO1 439   1 16 
  
16362 T > C MT-DLOOP    3 3089 
P037 H1a3a 534 C > T MT-DLOOP    1 36 
  
9182 G > A MT-ATP6 219 S > N 46 2 21 
P038 H56 14869 G > A MT-CYB 41   1 50 
  
16270 C > T MT-DLOOP    2 1003 
  
16311 T > C MT-DLOOP    3 3659 
2558 A > G MT-RNR2  rRNA  1 1 
3774 A > G MT-ND1 156   1 - P039 H13a1a 
12568 C > T MT-ND5 78   1  
6734 G > A MT-CO1 277   1 94 
11836 A > G MT-ND4 359   1 2 
16183 Del MT-DLOOP    1 23 
P040 J1c8a 
16241 A > G MT-DLOOP    1 97 
P041 J2b1a1         
152 T > C MT-DLOOP    6 3807 
523-524 delAC MT-DLOOP    11  
3083 T > C MT-RNR2  rRNA  1 13 
8701 A > G MT-ATP6 59 T > A 58 1 6017 
9909 T > C MT-CO3 235 F > L 22 1 7 
11654 A > G MT-ND4 299 T > A 58 1 58 
12373 A > G MT-ND5 13 T > A 58 1 13 
13105 A > G MT-ND5 257 I > V 29 2 1503 
P042 K1a4a1 
16342 T > C MT-DLOOP    1 110 
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
2861 A > G MT-RNR2  rRNA  1  
11914 G > A MT-ND4 385   2 2063 P043 H3b5 
14002 A > G MT-ND5 556 T > A 58 1 65 
P044 U5b1g 16519 T > C MT-DLOOP    3 11217 
524 insCA MT-DLOOP    7 9 
8639 T > C MT-ATP6 38 I > T 88 (C0) 1 7 
14572 A > G MT-ND6 34   1 3 
16093 T > C MT-DLOOP    4 984 
P045 K1a+195 
16111 C > T MT-DLOOP    2 486 
13575 C > T MT-ND5 413   1 3 
16180 A > G MT-DLOOP    1 7 P047 K1a 
16249 T > C MT-DLOOP    1 363 
P049 H1+16189         
6590 T > C MT-CO1 229   1 2 
10199 C > T MT-ND3 47   1 10 P050 H3ap 
16042 G > A MT-DLOOP    1 14 
146 T > C MT-DLOOP    1 3613 
709 G > A MT-RNR1    5 2404 P052 H13a1a1 
16261 C > T MT-DLOOP    1 1339 
523-524 delAC  MT-DLOOP    11  
10463 T > C MT-TR  tRNA  1 902 P053 J1c2e 
14593 insC MT-ND6 27   1  
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
523-524 delAC  MT-DLOOP    11  
9490 C > T MT-CO3 95 A > V 64 1 9 P054 J1c2e2 
14259 G > A MT-ND6 139 P > S 264 (C0) 1 14 
10398 A > G MT-ND3 114 T > A 58 1 7972 
P055 T1a1 
15977 C > T MT-ATT   tRNA 1 3 
1694 T > C MT-RNR2   rRNA 1 11 
5960 C > T MT-CO1 19   1 9 P056 H1e1a 
10544 C > T MT-ND4L 25   1 3 
P058 H1 16171 A > G MT-DLOOP    1 26 
239 T > C MT-DLOOP    1 240 
P059 H1at 
2501 C > T MT-RNR2   rRNA 1 1 
6182 G > A MT-CO1 93   1 64 
6908 T > C MT-CO1 335   1 6 P062 H3at1 
13105 A > G MT-ND5 257 I > V 29 2 1503 
8475 C > T MT-ATP8 37 P > L 58 (C15) 1 1 
11928 A >G MT-ND4 390 N > S 46 1 57 
13056 C > T MT-ND5 240   1 13 
P064 T2c1d1 
14544 G > A MT-ND6 44   2 56 
5046 G > A MT-ND2 193 V > I 29 1 401 
9182 G > A MT-ATP6 219 S > N 46 2 21 
16270 C > T MT-DLOOP    2 1003 
P065 H56 
16311 T > C MT-DLOOP    3 3659 
523-524 delAC MT-DLOOP    11  P066 A2 
7830 G > A MT-CO2 82 R > H 29 1 20 
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Individual Haplo- group 
Nucleotide 
position 
Base 
change Gene 
Amino acid 
position 
Amino acid 
change 
Grantham 
value* 
Number of samples 
that present the 
variant 
Frequency in 
GenBank (18363 
sequences) 
14178 T > C MT-ND6 166 I > V 29 1 473 
14755 A > G MT-CYB 3   1 51 
14861 G > A MT-CYB 39 A > T 58 1 46 
  
        
Variants that are not defining the haplotype of the sample are shaded and variants never reported are bold in red. 
* The Grantham value was retrieved from mtSNP database and reflects the physicochemical differences between the original and altered amino 
acid residues (Grantham et al, 1974). Grantham values larger than 50 are described as radical amino acid replacements and those with 
Grantham values less than 50, are considered as conservative replacements. In bold blue there is shown the predicted Grantham value and the 
class assigned by Align-GVGD. 
 
